Bioceros Competitors, Revenue, Alternatives and Pricing

Claim your profile


Utrecht, Netherlands
Total Funding:N/A
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Bioceros's estimated annual revenue is currently $9.9M per year.(?)
  • Bioceros's estimated revenue per employee is $155,000

Employee Data

  • Bioceros has 64 Employees.(?)
  • Bioceros grew their employee count by 31% last year.
  • Bioceros currently has 1 job openings.

Bioceros is one of Europe's premier providers of GMP-ready protein producing cell lines that operates from within the PolPharma Group. Bioceros has developed a proprietary animal-component free, suspension CHO platform (named CHOBC®) that is used for stable Cell Line Development. All the Cell Line Development work that we perform is Quality Controlled. We have generated cell lines producing proteins ranging from blood proteins and monoclonal antibodies to fusion proteins and enzymes. For monoclonal antibodies, our services start based on customers wishes, either with cDNA sequences to be expressed or by generation of antibodies in rodents, followed by cloning of the sequences from selected hybridomas. Further services include immunoassays, with a particular emphasis on cell based assays, as well as down-stream process development and full analytical analysis (i.e. glycan structures, charge variants and many other relevant quality attributes). Additionally, our CHOBC® platform has enabled us to generate high-producing biosimilar expressing cell lines that have been extensively analyzed to optimize the process conditions and thus yield highly similar antibodies when compared to the originators. These cell lines are available for out-licensing or co-development in various stages of development. The people at Bioceros strongly believe that true and close collaboration speeds up selection and development of clients most viable drug candidates. Therefore, the programs are designed in a flexible way, and scientists and staff involved in the programs are easily approachable.